Bayer HealthCare names Dieter Weinand president effective Aug. 1

LEVERKUSEN, Germany — Bayer last week named Dieter Weinand president of Bayer HealthCare Pharmaceuticals effective Aug. 1. At that time, he also will join the executie committee of Bayer HealthCare. 

"We welcome Dieter Weinand to our management team," said Olivier Brandicourt, Bayer HealthCare CEO. "Based on his extensive commercial experience in the pharmaceutical industry, Dieter Weinand will drive the growth of our pharmaceutical business further and maximize the value of our product portfolio." 

Weinand has more than 25 years of experience in various commercial operative and strategic executive roles in the pharmaceutical industry, and has been responsible for different markets such as Asia-Pacific, Europe, Middle East, Africa, Latin America and the United States at companies including Pfizer and Bristol-Myers Squibb, as well as for the marketing of products in different therapeutic areas such as cardiology, oncology, pulmonology, dermatology, immunology and inflammation. 

He will join Bayer HealthCare from Otsuka Pharmaceutical Development & Commercialization in Princeton, N.J., where he is currently responsible as president, global commercialization for a $13 billion revenue healthcare business.

Weinand earned an M.S. in Pharmacology/Toxicology from Long Island University in New York, as well as a B.A. in Biology from Concordia College in New York.

Weinand, who was born in Boppard, Germany, is married and has three children.